Pfizer’s Torcetrapib Shown Ineffective At Slowing Coronary Plaque Build-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Uncertainty remains as to whether failures are class related or specific to torcetrapib, lead investigator Nissen tells “The Pink Sheet” DAILY.